Navigation Links
Adeona CEO to Present at the NYC Medtech Forum
Date:10/5/2011

ANN ARBOR, Mich., Oct. 5, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that James S. Kuo, M.D., M.B.A., the Company's Chief Executive Officer and Chairman, will provide a brief update on its Alzheimer's program at the NYC Medtech Forum. Adeona will be one of four featured companies at the invitation-only event on Tuesday evening, October 11, 2011, at the offices of Kaye Scholer, LLP in New York City.

"We are thrilled to invite Dr. Kuo back to the NYC Medtech Forum following his presentation on Adeona's CNS clinical development programs last December," said John R. Lieberman, CPA, Managing Director at Perelson Weiner, LLP. "Our exclusive forum offers a unique platform for companies in the life science sector to share the potential of their clinical programs and product candidates with our select invited guests."

About NYC Medtech

NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes. This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners, etc. The NYC Medtech program introduces invited participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum. The NYC Medtech initiative was created and founded by John R. Lieberman at Perelson Weiner, LLP, along with Wendy Brown of Merrill Lynch and Ted King of SaddleRock Advisors. For more information about NYC Medtech, please visit the website at www.nycmedtech.com.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
2. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
3. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
4. InterMune to Present at Canaccord Adams Conference
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
8. Bionovo to Present at Canaccord Adams Global Growth Conference
9. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2020)... ... April 20, 2020 , ... ... MA, announced today that Omixon’s founder and chairman Dr. Attila Berces returns as ... product Holotype HLA since 2014 before stepping into the CEO role in 2017. ...
(Date:4/7/2020)... ... April 06, 2020 , ... Red Nucleus, a leading provider ... announced the release of at-home virtual learning resources for all client partners. , ... safety of our employees as we continue to implement measures to safeguard the ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... announce the signing of a Joint Development Agreement that builds on each company’s ... is a global leader in the supply of high-quality insect pheromones as well ...
(Date:3/13/2020)... ... 12, 2020 , ... Today, DuPont Nutrition & Biosciences (DuPont) ... a pioneer in the field of microbiome science, which focuses on microbes that ... health, based at University College Cork and Teagasc Moorepark. , Representatives from both ...
Breaking Biology Technology:
(Date:5/6/2020)... ... May 06, 2020 , ... The LaunchPort™ ... the latest out-of-state company to partner with the device accelerator located in ... a point-of-care analyzer capable of accurately performing enzyme-linked immunosorbent assays (ELISAs), the ...
(Date:4/30/2020)... ... , ... Pebble Labs USA Inc. , a biotechnology company developing solutions ... mission of improving global food security, announced today that they have been selected as ... and Ag-Tech ' virtual event, a global initiative to drive innovation in feeding future ...
(Date:4/26/2020)... ... April 23, 2020 , ... A team of researchers at the ... synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is ... potential treatment option for COVID-19. , The efforts are being led by Mone Zaidi, ...
Breaking Biology News(10 mins):